Close Menu
NEW YORK (GenomeWeb News) - Consumer genomics firms could potentially help the US Food and Drug Administration track post-marketing adverse drug reactions, and the agency is interested in partnering with these firms, according to a high-ranking agency official.
 
Lawrence Lesko, director of FDA’s Office of Clinical Pharmacology, said the agency has already begun preliminary discussions with some undisclosed personal genomics firms “to evaluate the feasibility” of forging such alliances.
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

Newsweek discusses the privacy issues raised by digital medicine.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.